KR20240021760A - 알츠하이머병의 치료 방법 - Google Patents

알츠하이머병의 치료 방법 Download PDF

Info

Publication number
KR20240021760A
KR20240021760A KR1020237039101A KR20237039101A KR20240021760A KR 20240021760 A KR20240021760 A KR 20240021760A KR 1020237039101 A KR1020237039101 A KR 1020237039101A KR 20237039101 A KR20237039101 A KR 20237039101A KR 20240021760 A KR20240021760 A KR 20240021760A
Authority
KR
South Korea
Prior art keywords
subject
administered
hydrochloride
daily dose
donepezil hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237039101A
Other languages
English (en)
Korean (ko)
Inventor
샤론 엘. 로저스
Original Assignee
아미리어드 파마 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아미리어드 파마 아이엔씨. filed Critical 아미리어드 파마 아이엔씨.
Publication of KR20240021760A publication Critical patent/KR20240021760A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237039101A 2021-05-19 2022-05-19 알츠하이머병의 치료 방법 Pending KR20240021760A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163190299P 2021-05-19 2021-05-19
US63/190,299 2021-05-19
US202163192398P 2021-05-24 2021-05-24
US63/192,398 2021-05-24
US202263331011P 2022-04-14 2022-04-14
US63/331,011 2022-04-14
PCT/US2022/030020 WO2022246059A1 (en) 2021-05-19 2022-05-19 Method of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
KR20240021760A true KR20240021760A (ko) 2024-02-19

Family

ID=84104208

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237039101A Pending KR20240021760A (ko) 2021-05-19 2022-05-19 알츠하이머병의 치료 방법

Country Status (8)

Country Link
US (3) US20220370443A1 (https=)
EP (1) EP4340834A4 (https=)
JP (1) JP2024518455A (https=)
KR (1) KR20240021760A (https=)
AU (1) AU2022275939A1 (https=)
CA (1) CA3217579A1 (https=)
MX (1) MX2023013537A (https=)
WO (1) WO2022246059A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60006145T2 (de) * 1999-07-30 2004-06-09 Zenyaku Kogyo K.K. Azaindolizinon-derivate und agenzien zur verbesserung der kognitiver fähigkeiten,die dieselben als aktive inhaltstoffe enthalten
JP2012512173A (ja) * 2008-12-15 2012-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アミロイド前駆体タンパク質の切断を誘導して新規断片を形成させる方法
CN102573839A (zh) * 2009-05-11 2012-07-11 加利福尼亚大学董事会 降低泛素化蛋白水平的方法
WO2012094612A1 (en) * 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Method of treating essential tremor

Also Published As

Publication number Publication date
AU2022275939A1 (en) 2023-11-16
CA3217579A1 (en) 2022-11-24
WO2022246059A1 (en) 2022-11-24
EP4340834A1 (en) 2024-03-27
US20220370443A1 (en) 2022-11-24
JP2024518455A (ja) 2024-05-01
US20250375444A1 (en) 2025-12-11
EP4340834A4 (en) 2025-04-02
MX2023013537A (es) 2024-02-06
US20240156812A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
JP2026001038A (ja) 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤
JP2023175694A (ja) ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドの組成物
US11554106B2 (en) Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin
US20070185080A1 (en) Pharmaceutical Compositions
US20100298397A1 (en) Method of treatment of obsessive compulsive disorder with ondansetron
KR20240021760A (ko) 알츠하이머병의 치료 방법
US12023315B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
CN117529318A (zh) 治疗阿尔茨海默病的方法
HK40103192A (zh) 治疗阿尔茨海默病的方法
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
US20240358693A1 (en) Methods of treating pain
US11752141B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
CA3162952C (en) Treating behavioral and psychological symptoms in dementia patients
KR20250084183A (ko) 다발성 경화증에 대한 치료용 티로신 키나제 저해제
WO2026052068A1 (zh) 药物组合物的用途
HK40071665B (zh) 在痴呆患者中治疗行为和精神症状
Ahmad Diaz et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
EA045669B1 (ru) Способы лечения поведенческих и психологических симптомов у пациентов с деменцией
MX2015003810A (es) Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.
HK40071665A (en) Treating behavioral and psychological symptoms in dementia patients
US20120302616A1 (en) Method of treatment of obsessive compulsive disorder with ondansetron
TW201919597A (zh) 利用新斯的明（neostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231113

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250519

Comment text: Request for Examination of Application